

Join Keystone Symposia
for the 2016 conference on:

HIV Persistence: Pathogenesis and Eradication

March 20–24, 2016

Resort at Squaw Creek | Olympic Valley, California | USA

Scientific Organizers:
David M. Margolis, Satya Dandekar and Susana T. Valente

*Joint with the conference on **HIV Vaccines***

The clearance of a retroviral infection is a herculean task and requires unraveling the mechanisms of viral persistence and host immune interactions. Recent studies of early therapeutic interventions and HIV-resistant cellular therapies have provided new insights into the development of HIV eradication strategies. This meeting will focus on all aspects of HIV persistence and eradication that include: (1) The understanding of persistent HIV infection; (2) Innate defenses against retroviral infection; (3) The interplay of the host inflammatory response and HIV pathogenesis; and (4) Novel concepts for viral eradication. Special attention will be paid to progress in the development of model systems to study latent infection as well as strategies to eradicate it. Emphasis will be placed on new, unpublished findings that will highlight novel insights and creative strategies to develop effective control and eradication of HIV infection.

Session Topics:

- Acute HIV Infection and Initial Transmission Events (Joint)
- Mechanisms of Persistent Infection
- Reservoirs & Persistence I & II
- Workshop: Obstacles to Cure
- Auxillary Genes and Host Restriction Factors
- Antiviral Host Response and Inflammation
- Cure Studies in Models and Man
- Immunotherapy (Joint)

Submitting an abstract is a great way of participating in the conference through poster presentation and possible selection for a short talk.

Scholarship & Discounted Abstract Deadline: Nov 19, 2015
Abstract Deadline: Dec 17, 2015
Discounted Registration Deadline: Jan 21, 2016

For additional details, visit **www.keystonesymposia.org/16X7**.

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery
www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230
a 501(c)(3) nonprofit educational organization

KEYSTONE SYMPOSIA
on Molecular and Cellular Biology

HIV Persistence: Pathogenesis and Eradication (X7)

Scientific Organizers: David M. Margolis, Satya Dandekar and Susana T. Valente

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

HIV Vaccines (X8)

Scientific Organizers: David C. Montefiori and Mario Roederer

March 20-24, 2016 • Resort at Squaw Creek • Olympic Valley, California, USA

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Global Health Travel Award Deadline: October 20, 2015 / Abstract & Scholarship Deadline: November 19, 2015 / Abstract Deadline: December 17, 2015 / Discounted Registration Deadline: January 21, 2016

SUNDAY, MARCH 20

Arrival and Registration

MONDAY, MARCH 21

Welcome and Keynote Address (Joint)

Anthony S. Fauci, NIAID, National Institutes of Health, USA
Combination Approaches to Prevent and Eradicate HIV Infection

Acute HIV Infection and Initial Transmission Events (Joint)

George M. Shaw, University of Pennsylvania, USA
Molecular Events Associated with HIV-1 Transmission and Acute Infection

Joseph Eron, University of North Carolina School of Medicine, USA
AHI, Therapy and Persistence

Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois, Switzerland
Therapeutic Interventions in Acute HIV Infection

Short Talk(s) Chosen from Abstracts

Workshop: Requirements for bnAb Induction (X8)

Short Talks Chosen from Abstracts

Mechanisms of Persistent Infection (X7)

Jonathan Karn, Case Western Reserve University, USA
Epigenetic Control of HIV Latency

Melanie M. Ott, University of California, San Francisco, USA
New Therapeutic Targets in Latent HIV Infection

John M. Coffin, Tufts University, USA
Cellular Proliferation and HIV Persistence

Susana T. Valente, Scripps Florida, USA
Eradication without Reactivation

Andrew P. Rice, Baylor College of Medicine, USA
Transcription Complex Regulation and HIV Latency

Short Talk Chosen from Abstracts

Immunologic Correlates of Sterilizing Immunity (X8)

Merlin L. Robb, Walter Reed Army Institute of Research, USA
Optimizing Quality and Durability of Immune Responses: Insights from RV 144 Follow-up Studies

Genoveffa Franchini, NCI, National Institutes of Health, USA
Correlates of Protection in Nonhuman Primate Models of SIV and SHIV Infection

Georgia D. Tomaras, Duke University Medical Center, USA
Key Epitopes and Ig Isotypes for Protection Against HIV-1

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, MARCH 22

Reservoirs and Persistence I (X7)

Janice E. Clements, Johns Hopkins University, USA
CNS and Other Reservoirs in SIV Infection

Satya Dandekar, University of California, Davis, USA
Early Establishment of HIV Reservoirs

J. Victor Garcia-Martinez, University of North Carolina at Chapel Hill, USA
Studies of Anti-Latency Therapy in the Humanized Mouse Model

Short Talk(s) Chosen from Abstracts

Epitopes, Structures and Ontogeny of Broadly Neutralizing Antibodies (X8)

Pamela J. Bjorkman, California Institute of Technology, USA
Structure-Based Design of Improved Antibodies Against HIV

William Schief, IAVI and The Scripps Research Institute, USA
Epitope-Focused HIV Vaccine Design

Dennis R. Burton, The Scripps Research Institute, USA
Broadly Neutralizing Antibodies to Guide HIV Vaccine Design

Jinal Nomathemba Bhiman, National Institute for Communicable Diseases and WITS University, South Africa
Viral Variants that Initiate and Drive Maturation of Broadly Neutralizing Antibodies

Short Talk(s) Chosen from Abstracts

Workshop 1: Obstacles to Cure (X7)

Short Talks Chosen from Abstracts

Auxillary Genes and Host Restriction Factors (X7)

Alan N. Engelman, Dana-Farber Cancer Institute, USA
HIV Integration and Viral Regulation

Stephen P. Goff, Columbia University, USA
Retroviral Silencing: Transcriptional and Post-Transcriptional Regulation

Michael Emerman, Fred Hutchinson Cancer Research Center, USA
Evolution of Host Antiviral Restriction Factors

Short Talk Chosen from Abstracts

Vaccine Concepts I (X8)

David C. Montefiori, Duke University Medical Center, USA
Magnitude and Breadth of Neutralization Required for Vaccine Protection Against HIV

John P. Moore, Weill Medical College of Cornell University, USA
How to Make and Use Multiple Native-Like SOSIP Trimers for Vaccine and Structural Studies

Bette T. Korber, Los Alamos National Laboratory, USA
HIV Vaccine Antigen Design

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

HIV Persistence: Pathogenesis and Eradication (X7)

Scientific Organizers: David M. Margolis, Satya Dandekar and Susana T. Valente

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

HIV Vaccines (X8)

Scientific Organizers: David C. Montefiori and Mario Roederer

March 20-24, 2016 • Resort at Squaw Creek • Olympic Valley, California, USA

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Global Health Travel Award Deadline: October 20, 2015 / Abstract & Scholarship Deadline: November 19, 2015 / Abstract Deadline: December 17, 2015 / Discounted Registration Deadline: January 21, 2016

KEYSTONE SYMPOSIA
on Molecular and Cellular Biology

HIV Persistence: Pathogenesis and Eradication (X7)

Scientific Organizers: David M. Margolis, Satya Dandekar and Susana T. Valente

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

HIV Vaccines (X8)

Scientific Organizers: David C. Montefiori and Mario Roederer

March 20-24, 2016 • Resort at Squaw Creek • Olympic Valley, California, USA

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Global Health Travel Award Deadline: October 20, 2015 / Abstract & Scholarship Deadline: November 19, 2015 / Abstract Deadline: December 17, 2015 / Discounted Registration Deadline: January 21, 2016

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, MARCH 23

Antiviral Host Response and Inflammation (X7)

Nicolas Chomont, University of Montreal, Canada
Homeostasis of the Latent HIV Reservoir

Yasmine Belkaid, NIAID, National Institutes of Health, USA
Talk Title to be Announced

Zhi Hong, GlaxoSmithKline, USA
Manipulating the Host Response in Persistence HIV Infection

Ivona Pandrea, University of Pittsburgh, USA
Natural Persistence of SIV

Short Talk(s) Chosen from Abstracts

Pathways Leading to Long-Term Protective Immunity Against HIV-1 (X8)

Bali Pulendran, Emory University, USA
Signaling Mechanisms

W. Ripley Ballou, GlaxoSmithKline Vaccines, Belgium
Inducing Long-Term Protection with Vaccines

Richard A. Koup, NIAID, National Institutes of Health, USA
T Cell Help

Speaker to be Announced

Short Talk(s) Chosen from Abstracts

Workshop 2 (X7)

Short Talks Chosen from Abstracts

Cure Studies in Models and Man (X7)

Nancie M. Archin, University of North Carolina, Chapel Hill, USA
Update on Studies in Man

John W. Mellors, University of Pittsburgh School of Medicine, USA
Biomarkers of HIV Persistence and Response to Therapeutic Interventions

Jerome A. Zack, University of California, Los Angeles, USA
Modeling CARs to Clear Infection in the Humanized Mouse Model

Short Talk Chosen from Abstracts

Vaccine Concepts II (X8)

Mario Roederer, NIAID, National Institutes of Health, USA
Passive Immunization in the SIV Model

Barton F. Haynes, Duke University Medical Center, USA
B Cell Lineage Approach to Broadly Neutralizing Antibodies

Peter D. Kwong, NIAID, National Institutes of Health, USA
Structure-Based Immunogen Design

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, MARCH 24

Keynote Address (Joint)

John R. Mascola, NIAID, National Institutes of Health, USA
Broadly Neutralizing Antibodies for HIV Prevention and Treatment

Immunotherapy (Joint)

David D. Ho, Rockefeller University, USA
Bispecific Antibodies

Michael Farzan, The Scripps Research Institute, USA
AAV-Expressed eCD4-Ig Can Protect Macaques from Robust SHIV-AD8 Challenges

David M. Margolis, University of North Carolina at Chapel Hill, USA
Enlisting Effector Cells to Clear Latent HIV Infection

Louis J. Picker, Oregon Health & Science University, USA
CMV-Based HIV Vaccines for HIV Prevention and Clearance

Short Talk(s) Chosen from Abstracts

Reservoirs & Persistence II (X7)

Sarah E. Palmer, Westmead Millennium Institute for Medical Research, Australia
Distinguishing Functional Proviral Genomes from Residual DNA

Vicente Planelles, University of Utah, USA
Novel Classes of HIV Latency-Reversing Agents

Daria J. Hazuda, Merck Research Laboratories, USA
Combination Therapy with HIV Latency-Reversing Agents

Bridging Innate and Acquired Immunity (X8)

Jeffrey V. Ravetch, Rockefeller University, USA
Optimizing Antibody-FcR Interactions

Margaret Ellen Ackerman, Dartmouth College, USA
FcR Effector Mechanisms

George K. Lewis, University of Maryland, USA
Qualitative and Quantitative Variables that Contribute to Fc-mediated Protection Against HIV-1

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X7)

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X8)

FRIDAY, MARCH 25

Departure